Sellas Life Sciences' Potential Leukemia Treatment Receives Second Rare Pediatric Disease Designation
Sellas Life Sciences' Potential Leukemia Treatment Receives Second Rare Pediatric Disease Designation
sellas life sciences的潛在白血病治療方案獲得第二個罕見兒童疾病認證。
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊